{
  "Variants Include": [
    {
      "Gene": "PARKIN",
      "variants": [
        {
          "HGVS": "NM_000304.3:c.136T>G",
          "cDNA Change": {
            "transcript": "NM_000304.3",
            "ref": "T",
            "alt": "G",
            "position": "136"
          },
          "Protein Change": {
            "ref": "C",
            "alt": "G",
            "position": "46"
          },
          "Description in input context": "c.136T>G (p.C46G) in PARKIN gene"
        }
      ]
    },
    {
      "Gene": "LRRK2",
      "variants": [
        {
          "HGVS": "NM_181808.2:c.136T>G",
          "cDNA Change": {
            "transcript": "NM_181808.2",
            "ref": "T",
            "alt": "G",
            "position": "136"
          },
          "Protein Change": {
            "ref": "C",
            "alt": "G",
            "position": "46"
          },
          "Description in input context": "c.136T>G (p.C46G) in LRRK2 gene"
        }
      ]
    }
  ],
  "Described Disease": {
    "Described Disease": "Parkinson's Disease",
    "MONDO": "MONDO:0005282"
  },
  "Experiment Method": [
    {
      "Assay Method": "Western Blot",
      "Material used": {
        "Material Source": "Cell line",
        "Material Name": "HEK293, HEK293T",
        "Description": "Experiments conducted using HEK293 and HEK293T cell lines."
      },
      "Readout type": "Quantitative",
      "Readout description": [
        {
          "Variant": "NM_000304.3:c.136T>G",
          "Conclusion": "Abnormal",
          "Molecular Effect": "partial loss-of-function",
          "Result Description": "PARKIN variant c.136T>G reduced ubiquitination activity by 60% compared to wild-type."
        },
        {
          "Variant": "NM_181808.2:c.136T>G",
          "Conclusion": "Abnormal",
          "Molecular Effect": "partial loss-of-function",
          "Result Description": "LRRK2 variant c.136T>G showed 40% reduced kinase activity compared to wild-type."
        }
      ],
      "Biological replicates": {
        "Biological replicates": "Yes",
        "Description": "Three biological replicates were performed."
      },
      "Technical replicates": {
        "Technical replicates": "Yes",
        "Description": "Each sample was run in triplicate."
      },
      "Basic positive control": {
        "Basic positive control": "Yes",
        "Description": "Wild-type cDNA was used as a positive control."
      },
      "Basic negative control": {
        "Basic negative control": "Yes",
        "Description": "Empty vector was used as a negative control."
      },
      "Validation controls P/LP": {
        "Validation controls P/LP": "No",
        "Counts": "N.D."
      },
      "Validation controls B/LB": {
        "Validation controls B/LB": "No",
        "Counts": "N.D."
      },
      "Statistical analysis method": {
        "Statistical analysis method": "ANOVA was used for statistical analysis."
      },
      "Threshold for normal readout": {
        "Threshold for normal readout": "Protein expression greater than 80% relative to control.",
        "Source": "Literature"
      },
      "Threshold for abnormal readout": {
        "Threshold for abnormal readout": "Protein expression less than 50% relative to control.",
        "Source": "Literature"
      },
      "Approved assay": {
        "Approved assay": "Yes"
      }
    },
    {
      "Assay Method": "Immunoprecipitation",
      "Material used": {
        "Material Source": "Cell line",
        "Material Name": "HEK293T",
        "Description": "Immunoprecipitation experiments conducted using HEK293T cell lines."
      },
      "Readout type": "Quantitative",
      "Readout description": [
        {
          "Variant": "NM_000304.3:c.136T>G",
          "Conclusion": "Abnormal",
          "Molecular Effect": "loss-of-function",
          "Result Description": "PARKIN variant c.136T>G showed 70% reduced interaction with ubiquitin ligase complex."
        },
        {
          "Variant": "NM_181808.2:c.136T>G",
          "Conclusion": "Abnormal",
          "Molecular Effect": "loss-of-function",
          "Result Description": "LRRK2 variant c.136T>G exhibited 50% reduced interaction with Rab proteins."
        }
      ],
      "Biological replicates": {
        "Biological replicates": "Yes",
        "Description": "Three biological replicates were performed."
      },
      "Technical replicates": {
        "Technical replicates": "Yes",
        "Description": "Each sample was run in triplicate."
      },
      "Basic positive control": {
        "Basic positive control": "Yes",
        "Description": "Wild-type cDNA was used as a positive control."
      },
      "Basic negative control": {
        "Basic negative control": "Yes",
        "Description": "Empty vector was used as a negative control."
      },
      "Validation controls P/LP": {
        "Validation controls P/LP": "No",
        "Counts": "N.D."
      },
      "Validation controls B/LB": {
        "Validation controls B/LB": "No",
        "Counts": "N.D."
      },
      "Statistical analysis method": {
        "Statistical analysis method": "ANOVA was used for statistical analysis."
      },
      "Threshold for normal readout": {
        "Threshold for normal readout": "Protein interaction greater than 60% relative to control.",
        "Source": "Literature"
      },
      "Threshold for abnormal readout": {
        "Threshold for abnormal readout": "Protein interaction less than 30% relative to control.",
        "Source": "Literature"
      },
      "Approved assay": {
        "Approved assay": "Yes"
      }
    }
  ]
}